Item 5.07 Submission of Matters to a Vote of Shareholders

On June 12, 2020, Adaptive Biotechnologies Corporation held its Annual Meeting of Shareholders. The following nominees were elected as directors, each to hold office until the annual meeting of shareholders on the date shown below or until his successor is elected and qualified, by the vote set forth below:





                                                                        Broker
      Nominee                   Class (1)      For        Withhold    Non-Votes
      David Goel                    I       72,878,339   11,385,039   16,206,222
      Robert Hershberg, PhD, MD     I       72,889,859   11,373,519   16,206,222
      Andris Zoltners, PhD          I       72,363,340   11,900,038   16,206,222


      (1) The terms of each of the Class I directors will expire as of the 2023
          annual meeting.

The appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending December 31, 2020 was ratified by the vote set forth below:





                              For       Against   Abstain
                          100,160,546   303,466    5,588

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses